Orthocell Receives $3.0m R&D Tax Refund
Filed with ASX · · 2 pages · English
• Orthocell confirms receiptof $3.0 million from the Australian FederalGovernment’sResearchand Development (R&D) Tax Incentive Program. • Non-dilutive addition to Orthocell’s cash reservesthat now stand at $49.6 million following receipt of the R&D tax refund. • The Company remains focused on driving rapid market adoption of Remplir™, supported by a strong debt-freebalance sheetand ongoinginvestme
Story so far
Earlier from Orthocell
- US Market and Operational Update
- Quarterly Activity Report & Appendix 4C
- Orthocell Posts Seventh Straight Record Revenue Quarter
- Orthocell Hits US Milestone - 100 Remplir Units Sold.
- Remplir Regulatory Application for US$750m EU-UK Market
Later from Orthocell
- Appendix 4D & Half-Year Financial Report
- Orthocell Appoints UK Distributor for Remplir
- Remplir Used in 23 Surgeries in Ukrainian soldiers
- OCC Secures Access to 221 U.S. Military Medical Centres
- Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell